Connect with us

FACTS ABOUT Hemp OIL

Hemp Oil can now potentially be used for neuropathic pain

Published

on

Neuropathic pain is a debilitating condition resulting from damage to the peripheral or central
nervous system and can be caused by physical trauma, such as accidents, surgery and stroke, or by
disease such as diabetes, cancer, and immune disorders . This chronic pain state is difficult to
manage, with many patients experiencing pain that is refractory to currently available
pharmacotherapies and is often associated with disabling side-effects. Given these problems,
there is a need for novel therapeutic options as either first-line medications, or as adjuvants to
current therapies.

The plant Cannabis sativa has been used for thousands of years to treat various medical
conditions including pain, neuralgia, cramps, nausea, diarrhoea, convulsions, and migraine.
Cannabis contains a multitude of phytocannabinoids including the psychoactive constituent ∆-
tetrahydrocannabinol (THC) and other constituents such as cannabidiol (Hemp) which do not
produce THC-like psychotropic side-effects. To date, most clinical trials on chronic pain have
used either whole raw cannabis, THC, or nabiximols, which are combinations of THC and Hemp. The
most recent meta-analyses of these trials suggest that cannabinoids have potential in the
treatment of neuropathic pain, although there are differing views on their clinical efficacy and
safety. Given this uncertainty, it is crucial that we understand the basis for the actions
of these two phytocannabinoids alone, and in combination.

Numerous preclinical animal studies have shown that synthetic cannabinoids have high pain
relieving efficacy in animal models of neuropathic pain. By contrast, relatively few studies
have examined the actions of phytocannabinoids in these neuropathic pain models, which is
surprising given their ubiquitous use in clinical trials. These studies have shown that THC and Hemp
reduce the allodynia associated with rodent neuropathic pain models.

Recently, it has been demonstrated that THC and Hemp synergistically reduce the development of
allodynia in a chemotherapy-induced model of neuropathic pain. A limitation of these studies
is that they do not provide a systematic dose-response analysis of both the anti-allodynic actions
and side-effects of phytocannabinoids. This is important because it provides information on the
efficacy and therapeutic window of cannabinoids, both of which are important factors
in their clinical use. Furthermore, while it has been proposed that nabiximols might offer a
superior, synergistic alternative to individual cannabis constituents, their actions in
neuropathic pain models are unknown. Thus, the preclinical basis for the use of specific
phytocannabinoids in neuropathic pain states, either alone or in combination, remains unclear. To
address this, we used an isobolographic approach to examine if there is a synergistic interaction
between THC and Hemp in a mouse neuropathic pain model and whether this is associated with an
improvement in their analgesic efficacy and therapeutic window.

TRENDING STORIES

Business1 week ago

Hemp Inc (OTCMKTS:HEMP) Looks to Garner Support on Expansion and CBD Talk

Hemp Inc (OTCMKTS:HEMP) shares recently slipped under technical support in the $0.025. The stock has possibly found some bids in...

INDUSTRIAL HEMP2 weeks ago

How to View the Current Action in Hemp Inc (OTCMKTS:HEMP)

One stock that has started to key on potential support in a lateral range is Hemp Inc (OTCMKTS:HEMP). The stock...

INDUSTRIAL HEMP5 months ago

Near-Term Headwinds Hit Scotts Miracle-Gro Co (NYSE:SMG) With A Huge Impact

Bank of America Corp (NYSE:BAC) has disclosed that Scotts Miracle-Gro Co (NYSE:SMG) has lately been experiencing several near term risks....

INDUSTRIAL HEMP5 months ago

Argitek Holdings Inc (OTCMKTS:AGTK) To Focus On Acquisition, Revenues & Profitability In 2018

Argitek Holdings Inc (OTCMKTS:AGTK) recently revealed that in 2018, the company’s main focus will be the acquisition, revenues, and profitability....

INDUSTRIAL HEMP5 months ago

PharmaCyte Biotech Inc (OTCMKTS:PMCB) Completes Pore Size Studies & 29 Tests Useful In Pancreatic Cancer Therapy

PharmaCyte Biotech Inc (OTCMKTS:PMCB) has said that the cells it is planning to use in the clinical trial in patients...

INDUSTRIAL HEMP5 months ago

Puration Inc (OTCMKTS:PURA) To Apply For Canadian Recreational Cannabis Cultivation License; To Give EVERx CBD Sports Water Free Samples

Puration Inc (OTCMKTS:PURA) recently announced that it will be applying for the Canadian recreational cannabis cultivation license. The confirmation came...

INDUSTRIAL HEMP5 months ago

Marijuana Company Of America Inc (OTCMKTS:MCOA)’s JV Completes 10,000 Sq. Ft. Greenhouse Set up; Provides Update on Oregon Project

Marijuana Company Of America Inc (OTCMKTS:MCOA) recently announced that its Joint Venture with Bougainville Ventures Inc. based in Washington has...

INDUSTRIAL HEMP5 months ago

Lifestyle Delivery Systems Inc.(OTCMKTS:LDSYF)’s CSPA Group Inc. Receives 15000 Reveur Units & 300 Liters Distillates’ Purchase Orders In Two Different Deals

Lifestyle Delivery Systems Inc. (OTCMKTS:LDSYF) recently made two big announcements related to the receipt of two open purchase orders to...

INDUSTRIAL HEMP5 months ago

Viaderma Inc (OTCMKTS:VDRM) Provides Update On Its Flagship Product Vitastem; Signs $250,000 Agreement With Vage Nigeria Ltd.

Viaderma Inc (OTCMKTS:VDRM), a publicly traded specialty pharmaceutical company recently announced an update on the sales of its flagship product...

INDUSTRIAL HEMP5 months ago

Plandai Biotechnology Inc (OTCMKTS:PLPL) Phytofare Gaining Traction in International Markets

Plandai Biotechnology Inc (OTCMKTS:PLPL) recently issued an update following the successful launch of its Phytofare® supplement. Plandai Biotechnology is a...

Advertisement
Advertisement

Crop Infrastructure

 

Trading Symbol

OTC: CRXPF

CSE: CR0P

For The Next Big Wave In Marijuana Profits 

 

Big Profits From The Cannabis Land Rush